Our Approach
The Right Molecule
The Right Study Design
The Right Indication
Our lead asset, STX-101, is a novel
5-HT3 Receptor Partial Agonist offering a clinically validated mechanism that ensures a safer therapeutic profile and avoids the Black Box safety limitations of full 5-HT3R antagonists.
The Right Indication
The Right Study Design
The Right Indication
Low Anterior Resection Syndrome (LARS) is a debilitating life-long post-surgical functional gastrointestinal disorder in rectal cancer survivors with no approved therapy, representing a $2B+ U.S. market opportunity. Two positive randomized trials demonstrate the efficacy of full 5-HT3R antagonists in LARS.
The Right Study Design
The Right Study Design
The Right Study Design
An enriched patient-centric design isolates the drug effect by using a decentralized clinical trial and engagement platform that normalizes patients to the placebo effect and supportive care prior to randomization.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.